The pharmaceutical industry is entering an era of mega-blockbusters, drugs with annual sales of $10 billion or more, that ...
As AstraZeneca braces for the impact of the U.S. “most favored nation” drug pricing policy, CEO Pascal Soriot suggests that a ...
AstraZeneca and GSK, the U.K.'s second and ninth most valuable companies, both saw first-quarter profits beat expectations early Wednesday.
Pharmalittle: We’re reading about warnings over Trump’s MFN plan, Purdue Pharma sentencing, and more
The Novartis CEO warned that Trump's drug pricing policy poses a “very difficult situation” and the reality will soon catch ...
On Tuesday, Novartis NVS CEO Vas Narasimhan said the Trump administration's "most favored nation" (MFN) drug pricing policy ...
Recent GlobalData POLI analysis showed a 35% decline in pharmaceutical launches across Europe in the ten months after the ...
The final major drugmaker President Donald Trump had pressed to accept a most-favored-nation deal has signed an agreement ...
ADVI Health’s Lindsay Greenleaf discusses how most-favored-nation drug pricing is playing out among specialty drugs. Drug ...
The renewed debate over Most Favored Nation (MFN) drug pricing in the United States reflects a legitimate frustration: ...
Today, President Donald J. Trump announced the 17th agreement with a major pharmaceutical manufacturer, Regeneron, to lower prescription drug prices that Americans pay for some of the world’s most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results